Literature DB >> 16959499

In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia.

Sean J Colloby1, Sanjeet Pakrasi, Michael J Firbank, Elaine K Perry, Margaret A Piggott, Jonathan Owens, David J Wyper, Ian G McKeith, David J Burn, E David Williams, John T O'Brien.   

Abstract

INTRODUCTION: Alterations in cholinergic function have been reported to be associated with dementia. The aim of this study was to investigate differences in the distribution of muscarinic acetylcholine receptors (mAChRs) using (R,R) 123I-iodo-quinuclidinyl-benzilate (QNB) and single photon emission computed tomography (SPECT) in dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD) and age-matched controls. 123I-QNB binding was also compared to the corresponding cerebral perfusion changes in the same subjects.
METHODS: 63 subjects (24 controls, 14 DLB, 25 PDD) underwent 123I-QNB and perfusion 99mTc-exametazine SPECT scanning. Image analysis, using statistical parametric mapping (SPM99), involved spatial normalisation of each image to a customised template, followed by smoothing and intensity normalisation of each image to its corresponding mean whole brain uptake. Group effects and correlations were assessed using two sample t tests and linear regression respectively.
RESULTS: Relative to controls, significant elevation of 123I-QNB binding was apparent in the right occipital lobe in DLB and right and left occipital lobes in PDD (height threshold p<or=0.001 uncorrected). PDD also showed significant loss in uptake in frontal regions and temporal lobes bilaterally that was not present in DLB. These patterns appeared to be independent of any corresponding rCBF changes.
CONCLUSION: Significant elevation of mAChRs in the occipital lobe was associated with DLB and PDD. This may relate to the visual disturbances that are prevalent in these disorders. Further studies are required in order to establish the role of mAChRs in visual function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959499     DOI: 10.1016/j.neuroimage.2006.07.026

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  9 in total

Review 1.  Neuroimaging and cognition in Parkinson's disease dementia.

Authors:  Lisa C Silbert; Jeffrey Kaye
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Muscarinic receptor binding changes in postmortem Parkinson's disease.

Authors:  Caitlin McOmish; Geoff Pavey; Catriona McLean; Malcolm Horne; Brian Dean; Elizabeth Scarr
Journal:  J Neural Transm (Vienna)       Date:  2016-11-21       Impact factor: 3.575

Review 3.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

Review 4.  Functional neuroimaging in Parkinson's disease.

Authors:  Martin Niethammer; Andrew Feigin; David Eidelberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

Review 5.  The role of neuroimaging in Parkinson's disease.

Authors:  Natasha S R Bidesi; Ida Vang Andersen; Albert D Windhorst; Vladimir Shalgunov; Matthias M Herth
Journal:  J Neurochem       Date:  2021-10-03       Impact factor: 5.546

Review 6.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

7.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

8.  Cholinergic and perfusion brain networks in Parkinson disease dementia.

Authors:  Sean J Colloby; Ian G McKeith; David J Burn; David J Wyper; John T O'Brien; John-Paul Taylor
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

Review 9.  Cholinergic imaging in dementia spectrum disorders.

Authors:  Roman Roy; Flavia Niccolini; Gennaro Pagano; Marios Politis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-16       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.